The Los Angeles Times
Sunday, November 19, 2006 — Page 1A
Mushrooms Take a Trip Back to the Lab:
Banned hallucinogens may have medical benefits, but results are unpredictable.
By Denise Gellene, Times Staff Writer
Resting on a hospital bed beneath a tie-dyed wall hanging, Pamela Sakuda felt a tingling sensation. Then bright colors started shimmering in her head.
She had been depressed since being diagnosed with colon cancer two years earlier, but as the experimental drug took hold, she felt the sadness sweep away from her, leaving in its wake an overpowering sense of connection to loved ones, followed by an inner calm.
“It was like an epiphany,” said Sakuda, 59, recalling the 2005 drug treatment.
Sakuda, a Long Beach software developer, was under the influence of the hallucinogen psilocybin, which she took during a UCLA study exploring the therapeutic effects of the active compound in “magic” mushrooms. Although illegal for general use, the drug has been approved for medical experiments such as this one.
Scientists suspect the hallucinogen, whose use dates back to ancient Mexico, may have properties that could improve treatments for some psychological conditions and forms of physical pain.
Long dismissed as medically useless, the banned mushrooms a staple of the psychedelic 1960s are taking a long, strange trip back to the lab.
The medical journal Neurology in June reported on more than 20 cases in which mushroom ingestion prevented or stopped cluster headaches, a rare neurological disorder, more reliably than prescription pharmaceuticals.
In July, researchers at Johns Hopkins University in Baltimore reported that mushrooms could instill a sense of spirituality and connection, a finding that scientists said could lead to treatments for patients suffering from mental anguish or addiction.
The research has been driven in part by the success of mood-altering pharmaceuticals, such as the antidepressant Prozac, which work on the same brain chemicals and pathways.
Nothing scientists have learned so far indicates that recreational use of mushrooms is safe. The psychological effects remain unpredictable. Deaths have been linked to mushroom intoxication. A Ventura County teen was killed by a car two years ago as she wandered naked across the 101 Freeway after eating mushrooms.
Even under the tightly controlled conditions of a clinical trial, some patients have had terrifying experiences marked by anxiety and paranoia; two people in the Johns Hopkins study likened the experience to being in a war.
The drug “takes your thoughts through a prism and turns them around,” Sakuda said.
Her drug trip left her with a sense of peace a serenity she hadn’t felt since her diagnosis.
“It was like rebooting a computer,” she said.
Drugs’ medical history
Forty years ago, the study of hallucinogens in therapy was a mainstream endeavor. The Swiss drug company Sandoz provided pharmaceutical-grade tablets of psilocybin and various researchers explored its use as a treatment for depression and other psychological problems.
Used for centuries during spiritual ceremonies by the Mazatec Indians in southern Mexico, mushrooms helped fuel the counterculture of the 1960s. Author Carlos Castaneda, while a graduate student at UCLA, wrote of his “magical time” with a Mexican shaman who introduced him to mushrooms and other hallucinogens.
In 1970, Congress made it illegal to posses hallucinogens, including psilocybin and LSD, by classifying them as Schedule I, meaning they had no legitimate medical use.
“All research was shut down,” said UCLA psychiatrist Dr. Charles S. Grob.
In the late 1990s, regulators began approving experiments again, sparked by discoveries in neuroscience that illuminated the biochemical basis of mood and consciousness. The advances focused on the complex role of the brain chemical serotonin a neurotransmitter that passes signals between cells.
Spread throughout the brain are a variety of receptors that respond to serotonin. In some instances, a flow of serotonin can alter moods, such as depression, euphoria, anxiety and aggression. The chemical is also believed to be involved with nausea, body temperature and appetite control.
Many hallucinogens, including psilocybin, mimic the action of serotonin on various receptors. When the drugs circulate in the brain, they can amplify, distort and cross signals. Sounds have colors, and motions become out-of-body experiences.
The drugs can trigger emotionally charged states and potentially dangerous behavior. Even the most optimistic psychedelic researchers acknowledge that at best psilocybin will become a special-purpose drug administered under tight supervision because reactions vary.
In addition to the sensory effects, hallucinogens create mental states in which patients become unusually open to suggestion, Grob said.
He wanted to test whether that ability could be used to alleviate the suffering of terminal cancer patients overcome with a sense of hopelessness.
Grob modeled his study after one conducted at Spring Grove Medical Center, a psychiatric hospital near Baltimore.
The Spring Grove patients took LSD. Grob is using psilocybin, which is shorter-acting and considered somewhat less risky. The drug is produced in small quantities under special Drug Enforcement Administration permits.
Grob has given the drug to seven terminally ill cancer patients.
In Sakuda’s case, weeks of counseling planted a desire to overcome her fears and sense of isolation. Since her diagnosis, she had avoided friends and kept her feelings bottled up.
The experiment took place in a comfortable hospital room, under the close watch of a medical team. She wore eyeshades and headphones with soft music playing.
Sakuda recalled sensing her husband’s sadness over her illness and feeling a burden lifted from her.
“It is not logical. It comes to you like that,” she said.
Sakuda died Nov. 10. Her husband, Norbert Litzinger, feels that the drug made a difference. “There was a rebirth around her and it didn’t stop.”
The power of the drug extends beyond psychological effects. Dr. John Halpern and colleagues at McLean Hospital in Boston have been looking at the ability of magic mushrooms to treat cluster headaches, which affect about 1 million Americans, mostly men.
The pain can be so severe that they are known as “suicide” headaches, occurring like clockwork at the same time each day, or the same month each year. No treatment has been shown to extend remissions from pain.
Halpern examined medical records of 48 patients who had taken hallucinogenic mushrooms and reported in Neurology that the majority of them found partial or complete relief from cluster attacks.
He speculated that the drug acts on the thalamus, a brain region populated with serotonin receptors. A clinical trial is needed to establish whether the mushrooms really work, Halpern said.
“These are not people you’d expect from the drug culture,” he said. “They are lawyers, teachers, business owners. They have a painful and debilitating condition, and found meaningful relief.”
Those who have used hallucinegenic mushrooms in the U.S. to ease their headaches are all lawbreakers.
They have become part of a new mushroom underground. Many of its denizens are like Bob Wold a 53-year-old maintenance worker and Little League coach who had never taken hallucinogenic drugs before. He knew they could be dangerous.
Wold, who lives near Chicago, said his headaches felt like an ice pick being jammed through his eye. Once, they made him drive his fist through a plaster wall at home. Another time he pounded his head against
the shower tiles so hard some of them cracked.
Seeking help, Wold stumbled across a website for cluster headache sufferers touting hallucinogenic mushrooms.
A man he met on the Internet mailed Wold 20 dried brown mushrooms. The recipe called for a very light tea, not strong enough to cause hallucinations.
After that, Wold started growing his own mushrooms.
Wold has formed an organization to fund research aimed at developing a pharmaceutical version of psilocybin.
But at home, he must make sure his crop is well hidden from his young grandchildren.
Former Washington lobbyist Stuart Miller, 49, described his secret life as a mushroom user as “bizarre.”
Miller had frequent cluster headaches and carried capsules containing ground mushrooms everywhere. As he passed through security daily on Capitol Hill, or made his way through an airport, Miller worried that a search would uncover the capsules “and my career would be gone.”
He was never caught. He has moved to Mexico to care for an aging parent.
Magic mushrooms grow wild in a nearby field.
The LA Times ran “Mushrooms Take a Trip Back to the Lab,” on the front page of its Sunday edition. The article describes MAPS-initiated research at Harvard/Mclean Hospital evaluating psilocybin as treatment for cluster headache, Dr. Charles Grob’s psilocybin/end-of-life anxiety pilot study at UCLA, and the recent Johns Hopkins study demonstrating that psilocybin induces mystical experiences. MAPS is in the early stages of protocol design for a study evaluating psyilocybin-assisted psychotherapy as a potential treatment for end-of-life anxiety. Unfortunately, although the article is mostly accurate, Times Staff writer Denise Gellene misleadingly prefaces her article by stating, “Nothing scientists have learned so far indicates that recreational use of mushrooms is safe,” a far cry from the truth.